NAD-boosting treatment shows no Parkinson's benefit in yearlong trial

A clinical trial involving 410 people with early Parkinson's disease found no clinical benefit from nicotinamide riboside (NR), a compound that increases cellular levels of nicotinamide adenine dinucleotide (NAD). The findings are published in JAMA.